GENERAL COMMENTS
This cross sectional study examined the glycaemic control and CVD risk profile of patients with type 2 diabetes diagnosed below and above 60 years of age and showed that younger age of diagnosis was associated with poorer diabetes control and adverse CVD risk profile.
Comments:
(1) Younger onset type 2 diabetes is generally defined with lower age of diagnosis (ie <40 yrs) than 60 years. Can the authors clarify the reason for choosing this cut off age?
(2) Majority of patients were under the care of tertiary hospital vs community/primary care centres. This may introduce bias to the conclusions. Comparison should be made between these 2 cohorts to determine if there is any difference in glycaemic control and CVD risk profiles. The patient numbers should be sufficiently large to allow this analysis to be done. 
This is an interesting cross-sectional study investigating glycaemic control, cardiovascular risk factors and treatment in patients with type 2 diabetes in Australia. It is a moderate sized population attending secondary and tertiary referral centres. That will lead to some patient selection bias.
• It is probable that there will be an over referral of overweight or obese poorly controlled patients to promote better control in young patients and this is the major flaw in this paper. It is difficult to know how the authors could disprove referral bias • Again, bias will depend on GP referral which is mentioned in the final paragraph of the discussion • Yet the same paragraph states the patients in this audit "are likely to be similar to patients attending diabetes clinics throughout Australia"
• Patient referral patterns may reflect the considerable proportion on insulin therapy in the study • I am not clear why the first 2 years were extracted from the study and the reasons should be made more explicit. It is not due to the excellent glycaemic control, hypertension control etc of the patients • I assume that BMI should > 30 kg/m2
• The lipid targets were very tight and probably accounts for the poor treatment gap -why so tight?
• The discussion (in my opinion) is too long • There is no journal in reference no 29.
VERSION 1 -AUTHOR RESPONSE
Thank you for your email and your detailed comments on our manuscript. In line with the comments received, we have revised the manuscript's methods, results, discussion and conclusions. We believe that our manuscript now provides a more balanced, reliable and up to date assessment of differences in the achieved levels and management of (1) glycaemic control and (2) cardiovascular risk factors among younger and older patients with type 2 diabetes.
Specifically, the authors feel that this manuscript warrants publication because: 1. The literature contains few studies examining the differences in glycaemic control and cardiovascular risk factors between younger and older patients with type 2 diabetes, and these report inconsistent findings. This is especially important given the prevalence of type 2 diabetes has increased by 70% in people aged 20-44 years and by 48% in people aged 45-64 years in the last three decades, making these the fastest growing groups of people with type 2 diabetes. Diabetes complications are related to disease duration and glycaemic control, thus younger people with diabetes, are at highest risk for end-organ damage.
2. Analysing data from 3496 adult participants of the Australian National Diabetes Audit (ANDA) we found that younger patients with significantly shorter disease duration were less likely to achieve recommended targets for glycaemic control, blood pressure and lipids than older patients. Younger patients were also more likely to be obese and to smoke compared with older patients. Of patients not achieving glycaemic, blood pressure, and lipid targets, younger patients were approximately twice as likely to either not be on therapy or to be above target
